SPEARs™ consist of a PPI disrupting domain and a cell penetrating domain. The PPI disrupting domain blocks oncogenic transcription and oncogenic signaling while altering the cell’s immune repertoire. The cell penetrating domain enables penetration into the cell’s cytoplasm or nucleus.

Unlike conventional peptides, SPEARs are engineered to have several important properties:

  • Enhanced stability: constructed to be resistant to proteases, enabling SPEARs to remain intact in vivo
  • Not immunogenic: demonstrated non-immunogenic profile preclinically and in the clinic, with no ADAs observed against SPEARs in development
  • Long half-life: the half-life of SPEARs is measured in days, providing prolonged exposure per dose and enabling more favorable clinical regimens
  • Cell permeability: SPEARs are designed to enter the cell and are tunable for cytoplasmic vs. nuclear localization
  • Blood-brain barrier permeability: enables treatment of tumors within the brain and central nervous system

A Rapidly Advancing Pipeline

Our pipeline of SPEARs™ is progressing through various stages of development.

View Pipeline